The Zinc-finger protein ASCIZ regulates B cell development via DYNLL1 and Bim
- Jurado, S; Gleeson, K; O'Donnell, K; Izon, DJ; Walkley, CR; Strasser, A; Tarlinton, DM; Heierhorst, J;
Publication Year 2012-08-27, Volume 209, Issue #9, Page 1629-39
- Journal Title
- The Journal of experimental medicine
- Publication Type
- Journal Article
- Developing B lymphocytes expressing defective or autoreactive pre-B or B cell receptors (BCRs) are eliminated by programmed cell death, but how the balance between death and survival signals is regulated to prevent immunodeficiency and autoimmunity remains incompletely understood. In this study, we show that absence of the essential ATM (ataxia telangiectasia mutated) substrate Chk2-interacting Zn(2+)-finger protein (ASCIZ; also known as ATMIN/ZNF822), a protein with dual functions in the DNA damage response and as a transcription factor, leads to progressive cell loss from the pre-B stage onwards and severely diminished splenic B cell numbers in mice. This lymphopenia cannot be suppressed by deletion of p53 or complementation with a prearranged BCR, indicating that it is not caused by impaired DNA damage responses or defective V(D)J recombination. Instead, ASCIZ-deficient B cell precursors contain highly reduced levels of DYNLL1 (dynein light chain 1; LC8), a recently identified transcriptional target of ASCIZ, and normal B cell development can be restored by ectopic Dynll1 expression. Remarkably, the B cell lymphopenia in the absence of ASCIZ can also be fully suppressed by deletion of the proapoptotic DYNLL1 target Bim. Our findings demonstrate a key role for ASCIZ in regulating the survival of developing B cells by activating DYNLL1 expression, which may then modulate Bim-dependent apoptosis.
- WEHI Research Division(s)
- Immunology; Molecular Genetics Of Cancer
- Link To PubMed Central Version
- Publisher's Version
- Open Access at Publisher's Site
- Rights Notice
- Copyright © 2012 Jurado et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
Creation Date: 2014-01-16 05:22:01Last Modified: 0001-01-01 12:00:00